Verastem, Inc. (VSTM) News
Track canonical SquawkNews coverage tagged to VSTM, Verastem, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 4 indexed stories across 3 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
VSTM Verastem Oncology doses first patient in target-d 203 phase 2 registration-directed trial of vs-7375 oral kras g12d (on/off) inhibitor
VSTM Verastem Oncology doses first patient in target-d 203 phase 2 registration-directed trial of vs-7375 oral kras g12d (on/off) inhibitor for kras g12d-mutated metastatic colorectal cancer
EQUITY | Jul 28, 2026, 08:01 PM UTC
H
Verastem price target lowered to $14 from $15 at RBC Capital
RBC Capital lowered the firm's price target on Verastem to $14 from $15 and keeps an Outperform rating on the shares as part of a broader research note previewing Q2 earnings in Biotech. The biotech sector has picked up
EQUITY | Jul 07, 2026, 11:32 AM UTC
H
VSTM: Reports Encouraging VS-7375 Data
Verastem Oncology reports encouraging clinical activity and favorable safety profile for VS-7375 in Phase 1/2 clinical study
EQUITY | Jun 23, 2026, 08:05 PM UTC
H
VSTM Shows Promise
VSTM's VS-7375 demonstrates clinical activity with favorable safety in Phase 1/2 trial for KRAS G12D-mutated solid tumors
EQUITY | Jun 23, 2026, 08:01 PM UTC